References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailGrip fatigue resistance and self-perceived fatigue in relation with sarcopenia and quality of life
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Bautmans, I et al

in Osteoporosis International (2015), 26(1), 265

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailIs there a specific pattern of lean/fat mass ratio in sarcopenic subjects?
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Croisier, Jean-Louis ULg et al

in Osteoporosis International (2015), 26(1), 261

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailClinical components linked to sarcopenia: the sarcophage study
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Petermans, Jean ULg et al

in Osteoporosis International (2015), 26(1), 258

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the registration of drugs to treat sarcopenia
Reginster, Jean-Yves ULg; Cooper, C; Rizzoli, R et al

in Osteoporosis International (2015), 26(1), 11

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailCan we identify patients to be treated in osteoarthritis?
Arden, NK; Richette, P; Cooper, C et al

in Osteoporosis International (2015), 26(1), 10

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailGlucosamine and chondroitin salts in the management of osteoarthritis in Europe
Reginster, Jean-Yves ULg

in Osteoporosis International (2015), 26(1), 8

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailTrabecular bone score (TBS) as a new complementary appproach for osteoporosis evaluation in clinical practice
Harvey, NC; Binkley, N; Brandi, ML et al

in Osteoporosis International (2015), 26(1), 7

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailCritical evaluation of promising markers for sarcopenia
CAVALIER, Etienne ULg; GADISSEUR, Romy ULg; GEBOES, Séverine ULg et al

in Osteoporosis International (2015), 26(1), 25

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailThe position of Strontium ranelate in today's management of osteoporosis
Reginster, Jean-Yves ULg; Brandi, ML; Cannata-Andia, J et al

in Osteoporosis International (2015), 26(1), 5

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailDenosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension
Papapoulos, S; Roux, C; Bone, HG et al

in Osteoporosis International (2015), 26(1), 4

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailOcanacatib antifracture efficacy and saftey in postmenopausal women with osteoporosis: results from the phase III long-term adonacatib fracture trial (LOFT)
McClung, MR; Langdahl, B; Papapoulos, S et al

in Osteoporosis International (2015), 26(1), 1

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailDevelopment and validation of the French version of a tool assessing patient's expectations in lower limb osteoarthritis
NEUPREZ, Audrey ULg; Delcour, JP; Fatemi, F et al

in Journal of Orthopaedics (2015), 12

Detailed reference viewed: 49 (29 ULg)
Full Text
Peer Reviewed
See detailA Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis.
Hiligsmann, Mickaël ULg; Evers, Silvia M.; Ben Sedrine, Wafa et al

in PharmacoEconomics (2015), 33(3), 205-224

BACKGROUND: Given the limited availability of healthcare resources and the recent introduction of new anti-osteoporosis drugs, the interest in the cost effectiveness of drugs in postmenopausal ... [more ▼]

BACKGROUND: Given the limited availability of healthcare resources and the recent introduction of new anti-osteoporosis drugs, the interest in the cost effectiveness of drugs in postmenopausal osteoporosis remains and even increases. OBJECTIVE: This study aims to identify all recent economic evaluations on drugs for postmenopausal osteoporosis, to critically appraise the reporting quality, and to summarize the results. METHODS: A literature search using Medline, the National Health Service Economic Evaluation database and the Cost-Effectiveness Analysis Registry was undertaken to identify original articles published between January 1, 2008 and December 31, 2013. Studies that assessed cost effectiveness of drugs in postmenopausal osteoporosis were included. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement was used to assess the quality of reporting of these articles. RESULTS: Of 1,794 articles identified, 39 studies fulfilled the inclusion criteria. They were conducted in 14 different countries and nine active interventions were assessed. When compared with no treatment, active osteoporotic drugs were generally cost effective in postmenopausal women aged over 60-65 years with low bone mass, especially those with prior vertebral fractures. Key drivers of cost effectiveness included individual fracture risk, medication adherence, selected comparators and country-specific analyses. Quality of reporting varied between studies with an average score of 17.9 out of 24 (range 7-21.5). CONCLUSION: This review found a substantial number of published cost-effectiveness analyses of drugs in osteoporosis in the last 6 years. Results and critical appraisal of these articles can help decision makers when prioritizing health interventions and can inform the development of future economic evaluations. [less ▲]

Detailed reference viewed: 21 (6 ULg)
Full Text
Peer Reviewed
See detailRetour au sport après plastie du ligament croisé antérieur : critères utilisés dans les cubs professionnels de football
Delvaux, François ULg; Rochcongar, P; Bruyère, Olivier ULg et al

in Science et Sports (2015), 30

Résumé Objectifs Analyser la démarche suivie par les médecins de clubs professionnels de football lorsqu’ils décident, en pratique quotidienne, d’autoriser le retour compétitif après plastie du ligament ... [more ▼]

Résumé Objectifs Analyser la démarche suivie par les médecins de clubs professionnels de football lorsqu’ils décident, en pratique quotidienne, d’autoriser le retour compétitif après plastie du ligament croisé antérieur chez un footballeur. Matériels et méthodes Trente-sept médecins responsables de clubs professionnels de football français et belges (Ligue 1, n = 15 ; Ligue 2, n = 14 ; Division 1 belge, n = 8) ont rempli un questionnaire à choix multiple concernant : (1) les critères utilisés afin de déterminer si un joueur est apte à reprendre la compétition après plastie du ligament croisé antérieur ; (2) l’importance relative de chacun de ces critères ; (3) le rôle éventuel d’intervenants spécifiques (kinésithérapeute…) dans cette décision. Résultats Plus de 80 % des médecins interrogés ont déclaré utiliser au moins huit critères (sur 17 proposés) afin d’évaluer la capacité d’un footballeur à reprendre la compétition après plastie du ligament croisé antérieur. Les trois critères considérés comme les plus déterminants étaient, par ordre d’importance : la stabilité dynamique du genou lors d’un exercice spécifique au football, la force musculaire et la récupération complète ou quasi complète d’amplitudes articulaires de flexion et d’extension de genou. Pour certains de ces critères (notamment la force musculaire), nous constatons cependant un manque de consensus sur les modalités pratiques d’évaluation, sur les paramètres ainsi que sur les valeurs-limites tolérées afin de garantir un retour sur terrain sécurisé. La prise en compte de l’avis du kinésithérapeute et du préparateur physique par une très nette majorité de médecins souligne l’importance d’un travail pluridisciplinaire. Conclusion L’utilisation de différents critères objectifs afin d’autoriser le retour compétitif après plastie du ligament croisé antérieur semble être une réalité dans le football professionnel. Des études supplémentaires devraient cependant contribuer à préciser les modalités des épreuves ainsi que des valeurs-seuils. ________________________________________ Summary Purpose To analyze how sport physicians decide, in their daily practice, when a professional soccer player with a reconstructed anterior cruciate ligament is able to get back to competitive activities. Materials and methods Thirty-seven physicians for professional French and Belgian soccer teams filled in a specific questionnaire dedicated to: (1) return-to-play criteria after anterior cruciate reconstruction; (2) the importance they assigned to each of these criteria in the return-to-play decision; (3) the potential role of professionals, such as physiotherapists or physical coaches in this decision. Results More than 80% of the respondents declared to use at least eight criteria in order to assess the player's ability to return to competitive soccer after anterior cruciate ligament reconstruction. The most important ones were (in order of importance): dynamic knee stability during a specific soccer exercise, muscle strength performance and normalization of knee flexion and extension ranges of motion. For most of these criteria (notably muscle strength), there was a lack of consensus about the choice of assessment parameters and the limit values allowing physicians to authorize or forbid the return-to-competition. A large majority of participants stated to take into consideration advices from physiotherapists or physical coaches for the return-to-play decision. Conclusion Sport physicians of professional soccer teams use relevant criteria to assess players’ ability to return to full sport after anterior cruciate ligament reconstruction. Further studies are required to determine the choice of assessment parameters and the limit values to assist physicians in return-to-play decisions. [less ▲]

Detailed reference viewed: 48 (6 ULg)
Full Text
Peer Reviewed
See detailDramatic osteonecrosis of the jaw associated with oral bisphosphonates, periodontitis and dental implant removal
Ayora, A F; HERION, Francine ULg; ROMPEN, Eric ULg et al

in Journal of Clinical Periodontology (2015), 42

Osteoporosis affects millions of elderly patients, and anti-resorptive drugs (ARD) such as bisphosphonates (BP) represent the first-line therapy. Despite the benefits related to the use of these ... [more ▼]

Osteoporosis affects millions of elderly patients, and anti-resorptive drugs (ARD) such as bisphosphonates (BP) represent the first-line therapy. Despite the benefits related to the use of these medications, osteonecrosis of the jaw is a significant complication in a subset of patients receiving these drugs. CASE PRESENTATION: This report documents a case of dramatic bisphosphonate-related osteonecrosis associated with periodontitis and dental implant removal in an osteoporotic patient treated with per os bisphosphonates for an uninterrupted period of 15 years. CONCLUSION: The aim of this report was to discuss the administration period of BP in the treatment of osteoporosis, the decision-making and clinical management of severe MRONJ and the indications for dental implant placement in these specific patients. [less ▲]

Detailed reference viewed: 28 (11 ULg)